{"id":"W2141453591","doi":"10.1158/1078-0432.ccr-11-0859","title":"Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c","year":2011,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Docetaxel; Mitoxantrone; Medicine; Prostate cancer; Internal medicine; Prednisone; Oncology; Cancer; Chemotherapy; Urology; Surgery; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001231112,0.001592038,0.001876039,0.0003513806,0.0004545733,0.001042184,0.0008652956,0.001442468,0.007677495],"category_scores_gemma":[0.0008244762,0.0006412831,0.0009538116,0.0003658198,0.001094965,0.0006179708,0.0003618554,0.002930507,0.0009812621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001067038,"about_ca_system_score_gemma":0.001773491,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001817339,"about_ca_topic_score_gemma":0.004855562,"domain_scores_codex":[0.9996732,0.000175382,0.00001087571,0.00005382925,0.00002202603,0.00006462381],"domain_scores_gemma":[0.9993204,0.000109581,0.0001464203,0.00004572176,0.00003015058,0.0003477612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9551161,0.01344497,0.001371074,0.0003575499,0.0005642365,0.00007419407,0.00007531775,0.0007238194,0.004635953,0.0001694197,0.002139755,0.02132753],"study_design_scores_gemma":[0.9201462,0.07618403,0.001667555,0.00001542899,0.0001565609,0.00005441992,0.00001840297,0.0003808571,0.0004483213,0.0000726927,0.0008457149,0.000009883308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907455,0.001878585,0.0003334499,0.0005413443,0.0002688057,0.003050871,0.001088629,0.0001280313,0.001964753],"genre_scores_gemma":[0.9848909,0.001730899,0.001152833,0.001023877,0.0002785667,0.003430258,0.00237899,0.00003219767,0.005081441],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007677495,"threshold_uncertainty_score":0.02568376,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2142580152465654,"score_gpt":0.5016571026383948,"score_spread":0.2873990873918294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}